Baricitinib for Refractory Eosinophilic Fasciitis: Myth or Reality?

J Rheumatol. 2022 May;49(5):546-547. doi: 10.3899/jrheum.211126. Epub 2021 Dec 15.

Authors

Gang Wang¹, Ning Zhuo², Jingyang Li¹

Affiliations

¹ Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou.
² Department of Nephrology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China.

PMID: 34911805
DOI: 10.3899/jrheum.211126

No abstract available

Publication types

Letter
Comment

MeSH terms

Azetidines* / therapeutic use
Eosinophilia* / drug therapy
Fasciitis* / diagnostic imaging
Fasciitis* / drug therapy
Humans
Purines
Pyrazoles
Sulfonamides

Substances

Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib

Supplementary concepts

Eosinophilic Fasciitis